As breakthrough drug companies look to new geographic markets, including emerging economies to target populations with rare diseases, many are coming up against unforeseen or underestimated barriers. Here, Arriello’s Kate Coleman reviews the findings of new transatlantic research which charts biotechs’ evolving commercialisation strategies and regulatory preparations, and the realities they are experiencing.
ra2 studio Shutterstock